Suchen
Emergent BioSolutions Inc
EBSZur Watchlist hinzufügen
6.800USD
-0.220-3.13%
Handelsschluss 09-18 16:00（ET）
347.81MMarktkapitalisierung
VerlustKGV TTM
Nachbörsliches Trading 19:00 (ET)6.800USD-0.030-0.44%
Nachbörsliches Trading 19:00 (ET)mehr Informationen über Emergent BioSolutions Inc Unternehmen
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Emergent BioSolutions Inc Profil
BörsenkürzelEBS
Name des UnternehmensEmergent BioSolutions Inc
IPO-datumNov 15, 2006
CEOPapa (Joseph C)
Anzahl der mitarbeiter900
WertpapierartOrdinary Share
GeschäftsjahresendeNov 15
Addresse300 Professional Dr
StadtGAITHERSBURG
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl20879
Telefon12406313200
Websitehttps://emergentbiosolutions.com/
BörsenkürzelEBS
IPO-datumNov 15, 2006
CEOPapa (Joseph C)
Führungskräfte von Emergent BioSolutions Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Ms. Stephanie Duatschek
Ms. Stephanie Duatschek
Executive Vice President, Chief Growth Officer
Executive Vice President, Chief Growth Officer
197.42K
--
Ms. Stephanie Duatschek
Ms. Stephanie Duatschek
Executive Vice President, Chief Growth Officer
Executive Vice President, Chief Growth Officer
197.42K
--
Ms. Stephanie Duatschek
Ms. Stephanie Duatschek
Executive Vice President, Chief Growth Officer
Executive Vice President, Chief Growth Officer
197.42K
--
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
267.95K
-1.48%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Emergent BioSolutions Inc?
Die fünf größten Anteilseigner von Emergent BioSolutions Inc sind: Mr. Joseph C. (Joe) Papa
Wie viele Institutionen halten Anteile an Emergent BioSolutions Inc (EBS)?
Mit Stand vom 2026Q1 halten 412 Institutionen Anteile an Emergent BioSolutions Inc, mit einem Gesamtmarktwert von etwa 42.30M, was 81.98% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -3370363.00 gestiegen.
Was ist die größte Einnahmequelle von Emergent BioSolutions Inc?
Am 2026Q1 erzielte das Geschäft mit MCM Product sales für Emergent BioSolutions Inc den höchsten Umsatz in Höhe von 168.00M, was 71.70% des Gesamtumsatzes entspricht.